The copyright line for this article was changed on 23 April 2015 after original online publication.
B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants
Version of Record online: 10 MAY 2013
©2013 The Authors. Acta Pædiatrica published by John Wiley & Sons Ltd on behalf of Foundation Acta Pædiatrica
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Volume 102, Issue 8, pages e347–e352, August 2013
How to Cite
Mine, K., Ohashi, A., Tsuji, S., Nakashima, J.-i., Hirabayashi, M. and Kaneko, K. (2013), B-type natriuretic peptide for assessment of haemodynamically significant patent ductus arteriosus in premature infants. Acta Paediatrica, 102: e347–e352. doi: 10.1111/apa.12273
- Issue online: 21 JUN 2013
- Version of Record online: 10 MAY 2013
- Accepted manuscript online: 24 APR 2013 02:29AM EST
- Manuscript Accepted: 19 APR 2013
- Manuscript Revised: 13 APR 2013
- Manuscript Received: 17 MAR 2013
- Mami Mizutani foundation
- Human Resource Chair
- B-type natriuretic peptide;
- Haemodynamically significant patent ductus arteriosus;
- Premature infants;
- Surgical ligation
Haemodynamically significant patent ductus arteriosus (hsPDA) is frequently observed in premature infants. This study was conducted to explore whether the blood BNP can be a valuable biomarker to assess the necessity of treatment for hsPDA in premature infants.
Serial measurements of the blood BNP were performed during the first 5 days of life in premature infants with hsPDA (Group I) and those without hsPDA (Group N). The definition of the hsPDA was the PDA requiring treatment, such as indomethacin administration and/or surgical ligation.
Forty-six subjects were enrolled. Compared with Group N, Group I showed significantly higher level of blood BNP at postnatal 24–96 h and demonstrated the peak value at postnatal 24–48 h. With the ROC curve using the data at postnatal 24–48 h in Group I, we deduced the predictive value of 250 pg/mL of blood BNP for indomethacin treatment. Similarly, with the ROC curve using the maximal value of blood BNP within the first 5 days of life, the predictive value of 2000 pg/mL for surgical ligation was deduced.
Blood BNP during early postnatal period can be a useful biomarker to assess the necessity of treatment for hsPDA in premature infants.